Zymeworks Inc.

NYSE:ZYME

12.52 (USD) • At close September 18, 2024
Bedrijfsnaam Zymeworks Inc.
Symbool ZYME
Munteenheid USD
Prijs 12.52
Beurswaarde 889,513,448
Dividendpercentage 0%
52-weken bereik 6.015 - 13.14
Industrie Biotechnology
Sector Healthcare
CEO Mr. Kenneth H. Galbraith C.A.
Website https://www.zymeworks.com

An error occurred while fetching data.

Over Zymeworks Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and

Vergelijkbare Aandelen

Rite Aid Corporation logo

Rite Aid Corporation

RAD

0.648 USD

ATI Physical Therapy, Inc. logo

ATI Physical Therapy, Inc.

ATIP

5.6 USD

Vicarious Surgical Inc. logo

Vicarious Surgical Inc.

RBOT

5.8 USD

Owlet, Inc. logo

Owlet, Inc.

OWLT

4.36 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)